GlassScriptPhysician profile
David Raymond Kalodner
NPI 1407231392
$15,635.66
in general payments reported to CMS, 2019-2025
47 companies · $2,582 in 2025
The $2,582 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,709 · 2020: $1,876 · 2021: $2,205 · 2022: $2,348 · 2023: $2,400 · 2024: $2,516 · 2025: $2,582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,497.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,571.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,555.21 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $1,384.19 | 2019-2025 | |
| Amgen INC. | $1,330.80 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbvie INC. | $1,173.15 | 2021-2025 | |
| Lilly USA, LLC | $1,107.46 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $959.41 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Janssen Pharmaceuticals, INC | $915.57 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $891.47 | 2019-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $377.37 | 2022-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $357.41 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Sanofi-Aventis U.S. LLC | $328.37 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $281.68 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $271.04 | 2019-2025 | Veozah, Myrbetriq |
| Dexcom, INC. | $262.53 | 2021-2025 | Dexcom G6 Transmitter |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kalodner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.